Regarding PCa treatment, it has been demonstrated that PPAT can affect the response to DCTX (docetaxel) treatment by upregulating the expression of BCL-Xl (B‐cell lymphoma extra-large), BCL‐2 (B‐cell lymphoma 2), and TUBB2B (β‐tubulin isoform 2B). This evidence concerns the gene PPAT and posterior cortical atrophy.